Skip to content

Role of Platelet Rich Plasma in Enhancing Graft Take in Chronic Venous Ulcers

Role of Platelet Rich Plasma in Enhancing Graft Take in Chronic Venous Ulcers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03526913
Enrollment
20
Registered
2018-05-16
Start date
2016-02-01
Completion date
2018-02-01
Last updated
2018-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Ulcer of Leg or Foot, Chronic Venous Hypertension With Ulcer and Inflammation

Keywords

chronic leg ulcers, PRP, split-thickness skin graft, platelet-rich plasma

Brief summary

Chronic venous ulcers are considered a problem with a big morbidity impact on both the health facilities and patients, skin-grafting have shown not so perfect outcomes with such ulcers. In this study, the investigators compare combining autologous platelet rich plasma treatments with partial skin grafting in chronic ulcers, the results were compared to using only partial skin grafting, and among various types of chronic resistant ulcers.

Detailed description

Fourteen patients had bilateral lower limb ulcers, and 6 of them had single large ulcers as follows; Fourteen patients with chronic venous ulcers (12 of which had bilateral ulcers, 2 had single large ulcers) Four patients, each with a single chronic post-traumatic ulcer Two patients with bilateral chronic lymphatic ulcers. After detailed history, physical examination and investigations (such as duplex), * Each patient with bilateral ulcers included in the study (14 patients) received treatment A on one ulcer and treatment B on the other ulcer. * In case of patients with single large ulcers (6 patients), treatment A was done on one half of the ulcer and treatment B on the other half of the ulcer (done in ulcers with an area greater than 10 x 10 cms). * Treatment A included pre-operative intra-lesional PRP injections in 1-week intervals for 3 times, followed by intra-operative intra-lesional injection of PRP prior to meshed graft placement. PRP was injected into the ulcer bed and ulcer edges using a sterile syringe. Treatment B included only placement of meshed graft, with no PRP treatment. * Pre-operative preparation: Ulcers were prepared by proper dressings and followed up until acquiring a clean bed. Debridement was done as needed to obtain clean base ready for graft placement. * PRP preparation: * 10 ml of blood was drawn from each patient intra operatively (autologous PRP). * Blood was collected in sterile tubes, Anticoagulant Citrate Dextrose (ACD) was used for anticoagulation, which is the same substance used to preserve viable platelets in blood banks for platelet transfer. * Tubes were centrifuged in Beckman Allerga X-12 centrifuge for 20 mins, 3000 rpm. * Each 10 ml of blood yielded an average of 3-4 ml of PRP. Calcium gluconate was added in a ratio of 1:10 to PRP. Post-operative assessment was carried out by follow up clinical examination, photography and weekly biopsy samples.

Interventions

PROCEDUREPRP

PRP: autologous platelet-rich plasma

PROCEDURESTSG

skin graft: Split Thickness Skin Grafting (STSG)

Sponsors

Menoufia University
CollaboratorOTHER
Noha Mohsen Omar
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

Comparison of combined autologous PRP and skin grafting to skin grafting alone in chronic leg ulcers (comparing one ulcer to another in bilateral cases, or one half of ulcer to the other in big ulcers)

Eligibility

Sex/Gender
MALE
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with chronic ulcers for at least 6 months. * Age ≧ 12 years.

Exclusion criteria

* Patients younger than 12 years of age. * Patients with diabetes or other diseases affecting tissue healing. * Patients with current ongoing pathologies in arterial or venous systems. * Patients with malignant ulcers. * Patients on corticosteroids or other drugs affecting tissue healing. * Patients with unrealistic expectations.

Design outcomes

Primary

MeasureTime frameDescription
Graft takemonthpercentage of graft take

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026